PXL770 [CAS 1523493-53-9]

PXL770 is an orally active, direct allosteric AMP-activated protein kinase (AMPK) activator. PXL770 decreases C26:0 levels, improves mitochondrial respiration, reduces expression of proinflammatory genes and induces expression of compensatory transporters (ABCD2/3) in ALD fibroblasts/lymphocytes. PXL770 normalizes plasma VLCFA levels, significantly reduces elevated VLCFA levels in brain and spinal cord in Abcd1 KO mice. PXL770 improves glycemia, dyslipidemia, and insulin resistance in ob/ob and high-fat diet (HFD) -fed mice. PXL770 can be used for the study of X-linked adrenoleukodystrophy (ALD), autosomal dominant polycystic kidney disease and nonalcoholic steatohepatitis (NASH) [1][2][3].

[1523493-53-9]

C23H18ClNO3S

423.91

O=C1NC2=C(C(O)=C1C3=CC=CC=C3)C(C4=C(O)C(CCCC5)=C5C=C4)=C(Cl)S2

AMPK

AMPK α1β1γ1; AMPK α1β2γ1; AMPK α2β1γ1

10mM

99.56

DMSO : 120 mg/mL (ultrasonic)

4°C (Powder, sealed storage, away from moisture and light)

Room Temperature